Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$511.45|
|52 Week High||US$242.03|
|52 Week Low||US$543.85|
|1 Month Change||3.32%|
|3 Month Change||14.21%|
|1 Year Change||109.83%|
|3 Year Change||150.96%|
|5 Year Change||366.40%|
|Change since IPO||19,859.02%|
Recent News & Updates
|TECH||US Life Sciences||US Market|
Return vs Industry: TECH exceeded the US Life Sciences industry which returned 56.4% over the past year.
Return vs Market: TECH exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: TECH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: TECH's weekly volatility (3%) has been stable over the past year.
About the Company
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Bio-Techne Fundamentals Summary
|TECH fundamental statistics|
Is TECH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TECH income statement (TTM)|
|Cost of Revenue||US$296.62m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.58|
|Net Profit Margin||15.07%|
How did TECH perform over the long term?See historical performance and comparison
0.3%Current Dividend Yield
Is Bio-Techne undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: TECH ($538.88) is trading above our estimate of fair value ($350.68)
Significantly Below Fair Value: TECH is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: TECH is poor value based on its PE Ratio (150.7x) compared to the US Life Sciences industry average (53.1x).
PE vs Market: TECH is poor value based on its PE Ratio (150.7x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: TECH is poor value based on its PEG Ratio (7x)
Price to Book Ratio
PB vs Industry: TECH is overvalued based on its PB Ratio (13.5x) compared to the US Life Sciences industry average (6.1x).
How is Bio-Techne forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECH's forecast earnings growth (21.5% per year) is above the savings rate (2%).
Earnings vs Market: TECH's earnings (21.5% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TECH's revenue (14.1% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: TECH's revenue (14.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (19.9%).
How has Bio-Techne performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TECH has a large one-off loss of $77.2M impacting its June 30 2021 financial results.
Growing Profit Margin: TECH's current net profit margins (15.1%) are lower than last year (31%).
Past Earnings Growth Analysis
Earnings Trend: TECH's earnings have grown by 18.8% per year over the past 5 years.
Accelerating Growth: TECH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TECH had negative earnings growth (-38.7%) over the past year, making it difficult to compare to the Life Sciences industry average (56.9%).
Return on Equity
High ROE: TECH's Return on Equity (8.9%) is considered low.
How is Bio-Techne's financial position?
Financial Position Analysis
Short Term Liabilities: TECH's short term assets ($510.6M) exceed its short term liabilities ($152.3M).
Long Term Liabilities: TECH's short term assets ($510.6M) do not cover its long term liabilities ($539.4M).
Debt to Equity History and Analysis
Debt Level: TECH's debt to equity ratio (22.3%) is considered satisfactory.
Reducing Debt: TECH's debt to equity ratio has increased from 11.1% to 22.3% over the past 5 years.
Debt Coverage: TECH's debt is well covered by operating cash flow (100.7%).
Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (18.3x coverage).
What is Bio-Techne current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TECH's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: TECH's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TECH is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TECH is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TECH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chuck Kummeth (61 yo)
Mr. Charles R. Kummeth, also known as Chuck, has been the Chief Executive Officer and President of Bio-Techne Corporation since April 1, 2013 and served as its Chief Financial Officer since January 2014. M...
CEO Compensation Analysis
Compensation vs Market: Chuck's total compensation ($USD15.89M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Chuck's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Experienced Management: TECH's management team is considered experienced (4.4 years average tenure).
Experienced Board: TECH's board of directors are considered experienced (6.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TECH insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Bio-Techne Corporation's employee growth, exchange listings and data sources
- Name: Bio-Techne Corporation
- Ticker: TECH
- Exchange: NasdaqGS
- Founded: 1976
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$21.145b
- Shares outstanding: 39.24m
- Website: https://www.bio-techne.com
Number of Employees
- Bio-Techne Corporation
- 614 McKinley Place N.E.
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 22:21|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.